Philadelphia, PA

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trials in systemic lupus erythematosus, myositis, systemic sclerosis and generalized myasthenia gravis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and follow us on LinkedIn and X (Twitter).

Uniquely Differentiated. Rapid. Elegant.

At Cabaletta, we are driven by the shared mission of developing cures, where a patients’ own cells are used to fight disease. We are building a culture grounded in the knowledge that successful cures can be achieved for patients if every member of the Cabaletta is focused on the success of the team. To nurture this, we make an active commitment to the well-being and continuous growth of each employee who joins the team. In this way, we are not only working to improve the lives of patients, but of everyone involved. #CabalettaCrew. 

We’re proud to be a Great Place to Work-Certified™ company! #GPTWcertified Check out what our employees say makes working here so great:  Working at Cabaletta Bio Inc | Great Place to Work®

 

About the Position:

 

We are seeking a talented and experienced Senior Scientist/Scientist with expertise in Molecular Genomics, specifically focused on Cell Therapy, to join our innovative Analytical Development team. Reporting to Principal Scientist, the successful candidate will play a key role in advancing our understanding of genetic mechanisms underlying CAART and CARTA cell therapies and will contribute to the development of novel genomic approaches to improve the manufacturing process which may lead to optimization of treatment efficacy and safety. This position requires a strong background in molecular biology, genomics, and cell therapy, as well as proficiency in next-generation sequencing (NGS) technologies and data analysis. The Senior Scientist/Scientist will collaborate closely with interdisciplinary teams to drive cutting-edge research projects aimed at translating genomic insights into transformative cell-based therapeutic strategies.

Join us in our mission to advance the field of cell therapy to cure autoimmune diseases through innovative molecular genomics approaches. If you are passionate about leveraging genomics to enhance the efficacy and safety of cell-based therapies, we invite you to apply and contribute your expertise to our dynamic team.

 

Responsibilities:

 

  • Lead and oversee projects at the intersection of molecular genomics and cell therapy, from conceptualization to execution and data analysis.
  • Design and optimize molecular biology protocols tailored to the specific requirements of cell therapy applications, including but not limited to gene editing, gene expression analysis, and single-cell genomics.
  • Implement state-of-the-art NGS technologies and tools cell therapy product characterization
  • Analyze genomic data sets to identify gene expression profiles, genetic variants, and signaling pathways associated with drug product manufacturing process unit operation.
  • Collaborate closely with cell biologists, immunologists, bioinformaticians, and clinical researchers to integrate genomic insights into the development and optimization of cell therapy products.
  • Generate and communicate research findings through presentations, scientific publications, and contributions to regulatory documents.
  • Stay abreast of emerging technologies, methodologies, and scientific literature in the fields of molecular genomics and cell therapy, and apply this knowledge to advance research objectives.
  • Provide technical guidance, mentorship, and training to junior scientists and research associates within the team.

 

Qualifications:

 

  • MS with degree in Molecular Biology, Genomics, Cell Biology, Immunology and 3-5 years of relevant experience or Ph.D.  or equivalent degree in Molecular Biology, Genomics, Cell Biology, Immunology, or a related discipline with 2-4 years of experience.
  • 3-5 years of hands-on experience in molecular biology techniques relevant to cell therapy, such as gene editing (e.g., CRISPR/Cas9), lentiviral transduction, and cell culture.
  • Proficiency in next-generation sequencing (NGS) technologies and associated data analysis tools, including variant calling, RNA sequencing, and single-cell genomics.
  • Demonstrated expertise in the application of genomic approaches to study cell therapy products, assess genomic integrity, and evaluate therapeutic efficacy.
  • Strong analytical skills with the ability to interpret complex genomic data sets and derive actionable insights to inform therapeutic development.
  • Excellent communication and collaboration skills, with the ability to work effectively in interdisciplinary teams and present scientific findings to diverse audiences.
  • Track record of scientific publications in peer-reviewed journals showcasing contributions to the field of molecular genomics or cell therapy.
  • Prior experience in project leadership, including experimental design, project planning, and supervision of research activities.
  • Knowledge of regulatory requirements and quality standards relevant to cell therapy research and development is advantageous.

 

Our name – Cabaletta – is derived from the operatic term that represents a rapid, repetitive, and technically challenging section of an operatic aria, designed to showcase the skills of the lead singer. Analogously, Cabaletta Bio strives to achieve rapid and repetitive product development, building on our indication prioritization and biologic platform that targets the driver of specific autoimmune diseases without the need for long-term immunosuppression.

 

For more information, please visit  https://www.cabalettabio.com/join-our-crew

 

Our most important asset is our people, and we offer competitive benefits, PTO, and stock option plans.

 

Cabaletta Bio is an equal opportunity employer. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law.

 

Cabaletta Bio, Inc. does not accept unsolicited resumes from recruiters, employment agencies, or staffing firms. To conduct business with Cabaletta, a Master Services Agreement (MSA) must be executed and confirmed prior to submitting any information relating to a potential candidate. Without a signed MSA, Cabaletta shall not be responsible to any individual or entity for any payment relating to any form of fee or compensation.

And, if a resume or candidate is submitted by a recruiter, an employment agency, or a staffing firm without a fully executed MSA, Cabaletta has the unrestricted right to pursue and hire any of those candidate(s) without any legal or financial responsibility to the recruiter, agency, and/or firm.